Assembly Biosciences, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Assembly Biosciences, Inc. (ASMB) reported Business Acquisition, Pro Forma Net Income (Loss) of -$26.35 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2015-05-08
- Assembly Biosciences, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2014-03-31 was -$4.50M.
- Assembly Biosciences, Inc. business acquisition, pro forma net income (loss) for fiscal 2014 was -$26.35M.
- Assembly Biosciences, Inc. business acquisition, pro forma net income (loss) for fiscal 2013 was -$20.35M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|
| 2014-12-31 | -$26.35M 10-K · filed 2015-03-16 | |
| 2014-03-31 | -$4.50M 10-Q · filed 2015-05-08 | |
| 2013-12-31 | -$20.35M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |